Clinical trials & pipeline
We are advancing a diverse and promising portfolio of clinically differentiated compounds through internal development and strategic external partnerships.
* Sairopa B.V. (Sairopa) and Exelixis have an exclusive clinical development and option agreement providing Exelixis the right to acquire ADU-1805
** Merck is sponsoring the study, and Exelixis is supplying the study drug, zanzalintinib
Disclaimer: The compounds presented are investigational or are being investigated for uses that have not been approved by the U.S. Food and Drug Administration. The safety and efficacy of these investigational compounds and/or investigational uses have not been established. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.
- Discovery/Preclinical Disc/Pre
- IND IND
- Phase 1 Phase 1
- Phase 1b/2 Phase 1b/2
- Pivotal Pivotal
COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC)
COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC)
Multi-TKI targeting MET/VEGFR/AXL/RET
Multi-TKI targeting MET/VEGFR/AXL/RET
COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC)
COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC)
STELLAR-311 (NET)
STELLAR-311 (NET)
STELLAR-304 (nccRCC)
STELLAR-304 (nccRCC)
STELLAR-303 (CRC)
STELLAR-303 (CRC)
STELLAR-002 (Solid tumors)
STELLAR-002 (Solid tumors)
STELLAR-001 (Solid tumors)
STELLAR-001 (Solid tumors)
KEYMAKER-U03 (RCC) – in partnership with Merck**
KEYMAKER-U03 (RCC) – in partnership with Merck**
XL092; Next-generation TKI targeting MET/VEGFR/AXL/MER
XL092; Next-generation TKI targeting MET/VEGFR/AXL/MER
STELLAR-311 (NET)
STELLAR-311 (NET)
STELLAR-304 (nccRCC)
STELLAR-304 (nccRCC)
STELLAR-303 (CRC)
STELLAR-303 (CRC)
STELLAR-002 (Solid tumors)
STELLAR-002 (Solid tumors)
STELLAR-001 (Solid tumors)
STELLAR-001 (Solid tumors)
KEYMAKER-U03 (RCC) – in partnership with Merck**
KEYMAKER-U03 (RCC) – in partnership with Merck**
Next-generation TF-TOPOi ADC
Next-generation TF-TOPOi ADC
ILT2-targeting mAb
ILT2-targeting mAb
IL13Rα2-TOPOi ADC
IL13Rα2-TOPOi ADC
DLL3-TOPOi ADC
DLL3-TOPOi ADC
* Sairopa B.V. (Sairopa) and Exelixis have an exclusive clinical development and option agreement providing Exelixis the right to acquire ADU-1805
** Merck is sponsoring the study, and Exelixis is supplying the study drug, zanzalintinib
- ADC = antibody-drug conjugate
- CRC = colorectal cancer
- DLL3 = delta-like ligand 3
- ILT2 = Ig-like transcript 2
- IL13Rα2 = interleukin 13 receptor alpha 2
- IND = investigational new drug application
- mAb = monoclonal antibody
- mCRPC = metastatic castration-resistant prostate cancer
- MMAE = monomethyl auristatin E
- nccRCC = non-clear cell renal cell carcinoma
- NET = neuroendocrine tumors
- NKG2A = natural killer cell receptor group 2A
- PD-L1 = programmed death-ligand 1
- PKMYT1 = protein kinase, membrane associated tyrosine/threonine 1
- RCC = renal cell carcinoma
- SCCHN = squamous cell carcinoma of head and neck
- SIRPα = signal regulatory protein alpha
- TF = tissue factor
- TKI = tyrosine kinase inhibitor
- TOPOi = topoisomerase inhibitor
- USP1 = ubiquitin specific peptidase 1
- VEGFR = vascular endothelial growth factor receptor
Disclaimer: The compounds presented are investigational or are being investigated for uses that have not been approved by the U.S. Food and Drug Administration. The safety and efficacy of these investigational compounds and/or investigational uses have not been established. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.